$YGYI CLR Roasters Awarded Supply Partnership with Hialeah, Florida’s Municipal Services

$OGI Receives Conditional Approval to Uplist to the TSX

$TGODF $TGOD Named Among Greenest Cannabis Firms, Renews Health Canada Licenses

• TGOD received a 100 percent organic rating from Toronto-based Corporate Knights magazine
• The company successfully renewed its Health Canada licenses authorizing the cultivation, processing and sale of cannabis from its Ancaster, Ontario, facility
• The cannabis company is lauded by the publication for its projected efficient, ecological use of renewable hydropower, which is scheduled to commence later this year

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), committed to production of organic cannabis, has been named one of the eco-friendliest cannabis firms in Canada. Corporate Knights, a Toronto-based publication, gave TGOD a 100 percent organic rating and cited its projected million square foot, ecologically efficient greenhouse in Valleyfield, Quebec (scheduled to operate later this year on renewable hydropower), as being a key component in the company’s anticipated growth (http://nnw.fm/3XkOg). As the budding cannabis industry continues to evolve, issues of sustainability and growing “greener” product are rising to the surface, and TGOD is currently one of only a handful of organic growers in Canada.

In an effort to meet the burgeoning market’s demand for product, cannabis producers have been focused on amassing large quantities of product. In this rush to produce, something has been neglected by most firms: tracking, disclosing and…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$BHAT Issuance, Sale of Additional Shares Exercise of Underwriter’s Over-Allotment Option in IPO

$YGYI Adds Pet Chews to HEMP FX Line, Brand Featured in Forbes Article

$LXRP Completes Initial Project with Canada’s National Research Council

– No chemical modification or degradation of Active Pharmaceutical Ingredients evidenced using DehydraTECH after acidic pH stability testing

– Strategically significant absence of covalent-bonded New Molecular Entity creation using DehydraTECH

Kelowna, British Columbia – August 8, 2019 – Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, announces the successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECHTM technology.

A primary goal of the R&D Program was to determine whether Lexaria’s DehydraTECH technology causes the formation of a new molecular entity (“NME”) through its processing. The Company is very pleased to report that all evidence aligns that no covalent-bonded NME is created with Lexaria’s technology. Technologies or processes, including certain forms of nanotechnology, that do create an NME are often burdened with much more extensive regulatory hurdles from agencies such as the FDA or Health Canada, to prove that the NME is safe for human consumption.

The R&D Program involved the preparation of over 50 formulations utilizing Lexaria’s DehydraTECH methodology and 33 of these were selected for in-depth analytical examination. Active pharmaceutical ingredients (“APIs”) tested included both THC and CBD from cannabis extract, pure nicotine, nicotine polacrilex, and pure ibuprofen. Formulations also tested both long chain fatty acid (“LCFA”) and a medium chain triglyceride (“MCT”) oils (as well as combinations of both oils together).

Analytical work included extensive use of liquid chromatography high-resolution mass spectrometry (“LC-HRMS”), nuclear magnetic resonance (“NMR”), and Fourier transform infrared (“FTIR”) spectroscopy. NMR was utilized as the main analytical technique due to its quantitative nature and ability to directly characterize the molecular construction of formulated products. The NMR and FTIR analyses demonstrated no shift in the spectral positioning of the API’s for all formulations tested, providing nearly incontrovertible evidence of a lack of any covalent-bonded NME.

In a 2016 report from the American Dental Association (www.ada.org) it was noted that 354 of 379 (or 93%) popular beverages commonly sold in retail stores, have a mildly acidic pH of 4.0 or lower. Many flavored beverage products from Gatorade, Powerade, Dasani and others have a pH of 2.73 to 3.05. The R&D program also tested Lexaria’s formulations at highly acidic levels of pH 1.12 and mildly acidic levels of pH 4.82, and the Company is delighted to report no chemical modification or presence of degradation of the API’s for both of the formulation classes analysed in this aspect of the program: cannabinoids and nicotine polacrilex.

Other formulation technologies by third parties that have not been tested for pH stability cannot be relied upon to deliver stable quantities of the API in question within an acidic beverage. Since mildly acidic formulas are used in the vast majority of beverages sold in North America today, pH stability testing is a necessary aspect of safely delivering cannabinoids within popular beverage formats and Lexaria’s technology is now proven capable of doing so.

The R&D Program was first announced on February 8, 2017, and although the specific goals within it have been achieved, an ongoing working relationship continues between the NRC and the Company to achieve new objectives. Additional studies underway with the NRC include studying nicotine polacrilex formulations for purposes of determining what other interactions may be occurring at a molecular level between the API and the fatty acids used in the DehdyraTECH(TM) processing methodology that may contribute to the improved pharmacology/performance of DehydraTECH(TM) formulations and our understanding thereof.

Lexaria extends its thanks to the talented and hard-working men and women at the NRC for their dedication and thorough scientific evaluation of Lexaria’s groundbreaking and patented DehydraTECH technology and formulations.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook https://www.facebook.com/lexariabioscience/

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(250) 765-6424 ext. 202

Or

NetworkNewsWire (NNW)

www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

$GGBXF Consumers Preferences Shaping the Retail Cannabis Market’s Direction

August 8, 2019

Palm Beach, FL –August 8, 2019 – The rise of the cannabis market is being driven by consumer acceptance and demand. Consumers are not just eating cannabis up, but they are also drinking, vaping, dabbing, smoking — and the list goes on. It’s been said that consumers are calling the shots and creating the direction that the markets will go in the future. Consumers are becoming more educated and are seeking retail cannabis products with a wide variety of products and of high quality. Increasing social consumer acceptance of cannabis products is driving up the value of cannabis derived/infused products.  According to a recent industry report there are four major submarkets: Flower; Edibles; Concentrates; and Other. In 2017 Flower revenues were $4.2 Billion and were 50% of the market. By 2022 it is estimated to be a $10.5 Billion while shrinking to only 36% of the market. In 2017 Edibles revenues were $1 Billion and were 12% of the market. By 2022 it is estimated to be a $4.1 Billion while growing to a 14% market share. In 2017 Concentrates revenues were $1.9 Billion and were 23% of the market. By 2022 it is estimated to be a $10.5 Billion market while growing to a 36% market share. Lastly, in 2017 Others revenues were $1.3 Billion and were 15% of the market. By 2022 it is estimated to be a $4.1 Billion while reducing to a 14% market share.  Active companies in the industry making moves to ready that include:  Choom™ Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Fire & Flower Holdings Corp. (OTCPK: FFLWF) (TSX-V: FAF), Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF), Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF).

The Report gave an overview of the market: “While seasoned consumers prefer smoking cannabis, other consumers are actually drawn to alternative forms that the plant comes in. Proprietary research from New Frontier reveals the products that most appeal to potential U.S. cannabis consumers: 69% solid edibles; 54% liquid edibles; 44% topicals; 36% joints or blunts; 32% vaporizers (vapes); 29% tinctures; 21% concentrates; and 19% pipes / water pipes.  The rising popularity in retail cannabis-derived products is being directed by consumers – and they’re using products for everything from relaxation to pain management.”

Choom™ Holdings Inc.  (CSE: CHOO) (OTCQB: CHOOF) BREAKING NEWS:  Choom™, an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that an Alberta provincially approved cannabis retail licensee (“Licensee”) is opening a cannabis retail store in Medicine Hat, Alberta operating under the Choom brand.

“We’re thrilled to see another Choom-branded store to open in Alberta.  We look forward to welcoming the Medicine Hat community as we share our unique retail experience.” said Chris Bogart, President and CEO of Choom.  “We are very pleased with the progress made in Alberta and look forward to our rapid expansion schedule for more Choom-branded cannabis retail stores to open throughout the province.”

The Choom-branded store is set to open on Saturday, August 10th.  The new store is located at 643 3 Street SE, Medicine Hat, Alberta. Opening hours are 10am – 10pm (Monday to Saturday), and 11am – 6pm (Sunday). For more information, visit choom.ca.

In addition to a licensing agreement with the Licensee, Choom has entered in a purchase agreement with the Licensee, pursuant to which, subject to receipt of approval from Alberta’s regulatory bodies, Choom will acquire the Medicine Hat store.   Read this and more news for Choom™ at:     https://www.financialnewsmedia.com/news-choo/

Additional industry related developments from around the markets:

Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) the Canadian company defining the future of cannabis worldwide, recently provided a corporate update on selected financial metrics for the fourth quarter of the Company’s Fiscal 2019 (“Q4 2019”) period ended June 30, 2019. This reiteration of guidance and clarification of operations is intended to update our investors as Aurora continues to demonstrate leadership in transparency and disclosure as the industry navigates throughs periods of volatility. Full results will be published prior to September 15, 2019, details for which will be provided in advance.

Based on a preliminary (unaudited) review, the Company anticipates net revenues for the quarter ended June 30, 2019 of between $100 million and $107 million (net of excise taxes), compared to $19.1 million in the period ended June 30, 2018, and compared to $65.1 million for the previous quarter ended March 31, 2019.  Fiscal Q4 2019 net cannabis revenue is expected to be between $90 million and $95 million, with growth anticipated across all key business segments including medical, both Canadian and international, and consumer markets.  The Company anticipates total net revenues for the fiscal year ended June 30, 2019 to be between $249 million – $256 million. The Company expects to report that production available for sale for Q4 2019 will be at the upper end of the range between 25,000 kg and 30,000 kg, ahead of previous guidance of 25,000 kgs.

Fire & Flower Holdings Corp. (TSX-V: FAF.V) (OTCPK: FFLWF) recently confirmed the closing of their transaction previously announced on July 24, 2019 (the “Transaction”). In addition, the common shares in the capital of Fire & Flower (the “Common Shares”) commenced trading on the Toronto Stock Exchange as of August 7, 2019.

The Transaction includes the issuance today by Fire & Flower of an 8.0% unsecured convertible debenture to an indirect wholly-owned subsidiary of Couche-Tard (the “Investor”) in the aggregate principal amount of approximately $26.0M, which principal amount of debenture is convertible by the Investor into 24,289,706 Common Shares (if converted in full) at a price of $1.07 per Common Share, representing a 9.9% ownership interest in Fire & Flower on a pro forma fully-diluted basis. The Investor has also been issued Common Share purchase warrants that, if exercised in full in accordance with the terms thereof, will subsequently increase the Investor’s ownership interest to 50.1% of Fire & Flower on a pro forma fully-diluted basis.

Green Growth Brands Inc. (CSE: GGB.CN) (OTCQB: GGBXF) announced that it expects to open its 100^th Seventh Sense Botanical Therapy (“Seventh Sense”) mall-based shop on Thursday, August 8^th. The first Seventh Sense shop opened in early February.

“This is a huge milestone for Green Growth Brands and Seventh Sense,” said Peter Horvath, CEO of Green Growth Brands. “We believe we have created the largest and most valuable network of brick and mortar CBD shops in the country.”

Trulieve Cannabis Corp. (CSE: TRUL.CN) (OTCQX: TCNNF) recently announced that the Company will begin trading on August 6, 2019 on the OTCQX^® Best Market under the symbol “TCNNF”, having graduated from the Pink^® market.

“We are thrilled to begin trading on the OTCQX Market just ahead of our one-year anniversary as a public company,” commented Kim Rivers , CEO of Trulieve Cannabis Corp. “This has been an exciting first year as we execute on our brand strategy and expansion plans to remain the dominant market leader in the fast-growing Florida market, gain momentum in California , Massachusetts and Connecticut , and enter into two new states by the end of 2019. This latest milestone should provide additional visibility within the investment community in order to build awareness of Trulieve more broadly and drive shareholder value.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press release issued above by Choom™ Holdings Inc. by a non affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:  editor@financialnewsmedia.com – +1(561)325-8757

$CNPOF $RIV $RIV.V Receives 12th Cannabis Retail Licence in Alberta

TORONTO, Aug. 8, 2019  – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSXV: RIV) (OTC: CNPOF) congratulates its portfolio company, YSS Corp. (“YSS“) (TSXV: YSS) (WKN: A2PMAX), on receiving its 12^th cannabis retail licence from the Alberta Gaming, Liquor and Cannabis Commission (“AGLC“). Operating under the YSS™ brand name, the newly licensed store is strategically located in a high-traffic suburban area in northwest Edmonton. YSS has six operational stores located in Calgary and Red Deer, with an additional two licensed locations expected to open in Vermilion and Vegreville within the next week.

“YSS continues to strengthen its hold on Alberta’s cannabis retail landscape, now boasting a total of 12 stores licensed by the AGLC,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “With plans to have all of its licensed stores operational by the end of Q3 2019, this announcement is a continued testament to YSS’s potential for growth and long-term profitability.”

Canopy Rivers currently holds approximately 8% of the issued and outstanding common shares in the capital of YSS on a fully-diluted basis. For more information regarding Canopy Rivers’ investment in YSS, please refer to the Company’s annual information form dated July 15, 2019 (“AIF“) filed with Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com. For additional information about YSS, please refer to YSS’s profile on SEDAR or their website at www.ysscorp.ca/investors.

About Canopy Rivers:

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the expectation that YSS will have an additional two licensed locations open within the next week; YSS’s plan to have all of its licensed stores operational by the end of Q3 2019; YSS’s potential for growth and long-term profitability; and other expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; YSS’s ability have an additional two licensed locations open within the next week and all of its stores open by the end of Q3 2019; changes in consumer preferences and demand; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ AIF, filed with Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

$BHAT Closing of Underwriter’s Over-Allotment Option in IPO

XIAMEN, China, Aug. 08, 2019 — via NetworkWire – Blue Hat Interactive Entertainment Technology (“Blue Hat”) (NASDAQ: BHAT), a producer, developer and operator of augmented reality interactive entertainment games and toys in China, announces the issuance and sale of an additional 141,114 ordinary shares priced at $4 per share, before underwriting discounts and commissions, resulting in gross proceeds of $564,456, before underwriting discounts and commissions and offering expenses, pursuant to the exercise of the underwriter’s over-allotment option in connection with Blue Hat’s previously announced underwritten initial public offering (“IPO”). After giving effect to the exercise of the underwriter’s over-allotment option, the total number of ordinary shares sold by Blue Hat in the IPO was 2,141,114 shares and gross proceeds were $8,564,456, before underwriting discounts and commissions and offering expenses.

The ordinary shares were approved for listing on The Nasdaq Capital Market and on July 26, 2019, commenced trade under the ticker symbol “BHAT.”

ViewTrade Securities Inc. (“ViewTrade Securities”), a global provider of brokerage, investment banking, corporate, advisory and trading platform services, acted as the sole book-running manager and sole underwriter for the offering.

A registration statement on Form F-1 (File No. 333-230051), including a prospectus relating to the offering, was filed with the U.S. Securities and Exchange Commission (the “SEC”) and on July 25, 2019, was declared effective by the SEC, and a registration statement filed pursuant to Rule 462(b) (File No. 333-232840) which increased the number of registered shares from 2,250,000 to 2,500,000 became effective upon filing with the SEC. The offering of the ordinary shares was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained on the SEC’s website (www.sec.gov) and may also be obtained from ViewTrade Securities Inc., Attention: Prospectus Department, 7280 W Palmetto Park Rd, Suite 310, Boca Raton, Florida 33433, or by email at ib@viewtrade.com. Please indicate your request for a prospectus.

Before you invest, you should read the prospectus and other documents Blue Hat has filed or will file with the SEC for more complete information about Blue Hat and the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Blue Hat Interactive Entertainment Technology

Blue Hat, headquartered in Xiamen, China, is a producer, developer and operator of augmented reality interactive entertainment games and toys, including interactive educational materials, mobile games, and toys with mobile game features. For more information, visit the company’s website at www.bluehatgroup.net.

About ViewTrade Securities Inc.

ViewTrade Securities is a U.S.-registered broker dealer providing brokerage, trading, investment banking & advisory services for U.S. retail investors and B2B to major financial institutions worldwide, including some of the largest institutions in their domestic markets. ViewTrade Securities’ Investment Banking Division offers capital raising and advisory services to growth-oriented companies both domestically and in emerging markets.

Forward-Looking Statements

This press release contains certain forward-looking statements, including statements with regard to Blue Hat’s proposed initial public offering. Words such as “will,” future,” “expects,” “believes,” and “intends,” or similar expressions, are intended to identify forward-looking statements. Forward-looking statements are subject to inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed initial public offering discussed above will be completed on the terms described. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Blue Hat, including, without limitation, the failure of customary closing conditions and the risk factors and other matters set forth in the prospectus included in the registration statement in the form last filed with the U.S. Securities and Exchange Commission. Blue Hat undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Blue Hat Contact
Blue Hat Interactive Entertainment Technology
Xiaodong Chen, President, Chief Executive Officer and Director
sean@bluehatgroup.net
86-592-228-0081

Corporate Communications  
Xiaoyun Zhang (张小云)
Corporate Communications
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Xiaoyun.Zhang@NetworkWire.com

$INMB Appoints Biotechnology Executive Edgardo Baracchini as New Board Member

LA JOLLA, Calif., Aug. 08, 2019 — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to announce that Edgardo (Ed) Baracchini, Ph.D., has joined the company’s board of directors.

“Ed is a fantastic addition to our board of directors,” said RJ Tesi, MD, INmune Bio’s Chief Executive Officer and Chief Medical Officer. “He brings extensive business development and deal-making experience to the company, which is a critical skill set, as we continue to advance our three drug candidates through clinical trials.”

Dr. Baracchini has an impressive biotech business development background with over 25 years of experience in structuring and negotiated research and development partnerships, mergers, acquisitions and licensing agreements.  He has negotiated over 80 business transactions with multinational pharmaceutical firms, biotechnology companies and prominent universities which resulted in transactions valued in excess of $5.3 billion.  He currently serves on the board of 4D Pharma PLC, as was previously Chief Business Officer of Xencor, Inc. (Nasdaq: XNCR), a biopharmaceutical company focused on autoimmune diseases. Prior to this, Dr. Baracchini was associated with Metabasis Therapeutics, where he quickly moved from the role of Vice President to Senior Vice President of Business Development.

“INmune Bio has very exciting clinical trials in cancer and Alzheimer’s disease,” said Baracchini. “I am looking forward to working closely with its seasoned leadership team, each of whom have demonstrated their own track record of success.”

About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Media Contact:
Antenna Group
Holly Dugan
(201) 465-8019
INmuneBio@AntennaGroup.com

Investor Contact: 
KCSA Strategic Communications
Valter Pinto / Daniela Guerrero
PH: (212) 896-1254 / (347) 487-6187
INmune@KCSA.com

$TGODF $TGOD Submits Application for NASDAQ Listing

$INMB Planning Phase II Trial of INB03 for Cancer Patients

• INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston
• Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment
• The annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides unique opportunities to connect scientists with the latest discoveries in the field

An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi slated to deliver several presentations. A news release outlining Tesi’s agenda at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease (http://nnw.fm/1jH3I).

“We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Tesi stated in…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$YGYI to Release 2019 Second Quarter and Six-Month Results

SAN DIEGO, Aug. 6, 2019  — Youngevity International, Inc. ( NASDAQ :YGYI ) a multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise and its newly acquired commercial hemp enterprise, announced today that it will host a conference call on Wednesday, August 14, 2019 at 1:00 PM Eastern Daylight Time, (10:00 AM Pacific Daylight Time), to discuss the Company’s financial results for the quarter ending June 30, 2019, which it plans to release that day.

Youngevity International’s senior management will host the call, led by Mr. Steve Wallach, Chairman and Chief Executive Officer, and joined by Mr. Dave Briskie, President and Chief Financial Officer. The purpose of the call will be to discuss its financial results, provide an update on current business trends and to answer questions that are submitted by shareholders, analysts, and other interested parties.

All interested parties can attend the event by clicking

https://InstantTeleseminar.com/Events/117068772 fifteen minutes prior to the start of the call, or by dialing 206 402 0100 and entering the access code 634174# at least five minutes prior to the start of the call. International and alternative numbers are available at https://InstantTeleseminar.com/Local/?eventid=117068772  

The conference call will be recorded and available for replay shortly after the conclusion of the call. An archived replay of the call will be available for approximately 3 months on the Company’s Investor Relations website: https://ygyi.com/.

About Youngevity International, Inc.

Youngevity International, Inc. ( NASDAQ: YGYI ), is a multi-channel lifestyle company operating in 3 distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise.  The Company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity, YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit YGYI.com. Be sure to like us on Facebook and follow us on Twitter.

Investor Relations
YGYI Investor Relations
800.504.8650
investors@ygyi.com

Media Relations
Trendlogic PR
800.992.6299
contact@trendlogicpr.com

$TGODF to Release Second Quarter 2019 Earnings Results on Aug 13

TORONTO, Aug. 6, 2019  – The Green Organic Dutchman Holdings Ltd. (“TGOD” or the “Company”) (TSX: TGOD) (US: TGODF) announced today that the Company expects to release its second quarter 2019 earnings on Tuesday, August 13, 2019 after market close. The Company will hold a conference call conducted by Brian Athaide, Chief Executive Officer, and Sean Bovingdon, Chief Financial Officer, on August 14, 2019 at 9:00 am Eastern Time to discuss the results and future outlook.

CONFERENCE CALL INFORMATION:

Date: August 14, 2019 | Time: 9:00 am Eastern Time
Participant Dial-In
Local – Toronto: (+1) 416 764-8688
Toll Free – North America: (+1) 888 390-0546
Conference ID – 37027015

Listen to Webcast
https://event.on24.com/wcc/r/2045003/C17F2A331332C2718597218C3F00D7C9

Replay Dial-In
Local – Toronto: (+1) 416 764-8677
Toll Free – North America: (+1) 888 390-0541
Replay Passcode: 027015 # [Available until Wednesday, August 21, 2019]

About The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

$GGBXF Opens More Than 100 CBD Shops In Seven Months

Total shop locations expected to reach 105 on Thursday, August 8^th

COLUMBUS, OH, Aug. 6, 2019 – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) (“GGB” or “the Company”) is pleased to announce that it expects to open its 100^th Seventh Sense Botanical Therapy (“Seventh Sense”) mall-based shop on Thursday, August 8^th. The first Seventh Sense shop opened in early February.

“This is a huge milestone for Green Growth Brands and Seventh Sense,” said Peter Horvath, CEO of Green Growth Brands. “We believe we have created the largest and most valuable network of brick and mortar CBD shops in the country.”

Seventh Sense shops retail high-quality botanical therapy CBD-infused personal care and beauty products at affordable prices. The product offering includes over 100 SKUs across bath, body, face, therapeutic, and sleep categories.

In addition to the network of shops, earlier this year, Seventh Sense launched its eCommerce site, ShopSeventhSense.com, allowing consumers access to hemp-derived CBD personal care and beauty products online.

A list of all current shop locations is available on ShopSeventhSense.com and is detailed below:

1. Fayette Mall, Lexington, KY
2. Glenbrook Square, Fort Wayne, IN
3. Hamilton Place, Chattanooga, TN
4. Castleton Square, Indianapolis, IN
5. Oxmoor Center, Louisville, KY
6. Mayfair, Wauwatosa, WI
7. CherryVale Mall, Rockford, IL
8. Providence Place, Providence, RI
9. Emerald Square, North Attleboro, MA
10. Las Vegas South Premium Outlets, Las Vegas, NV
11. South Shore Plaza, Braintree, MA
12. Penn Square Mall, Oklahoma City, OK
13. Opry Mills, Nashville, TN (location #1)
14. Opry Mills, Nashville, TN (location #2)
15. King of Prussia, King of Prussia, PA
16. The Streets at Southpoint, Durham, NC
17. Arizona Mills, Tempe, AZ (location #1)
18. Arizona Mills, Tempe, AZ (location #2)
19. Park Place, Tucson, AZ
20. Solano Town Center, Fairfield, CA
21. Brea Mall, Brea, CA
22. Tucson Mall, Tucson, AZ
23. Greenwood Park Mall, Greenwood, IN
24. Battlefield Mall, Springfield, MO
25. Wolfchase Galleria, Memphis, TN
26. Orland Square, Orland Park, IL
27. University Park Mall, Mishawaka, IN
28. Imperial Valley, El Centro, CA
29. Colorado Mills, Lakewood, CO
30. Park Meadows, Lone Tree, CO
31. Chicago Ridge Mall, Chicago Ridge, IL
32. Woodfield Mall, Schaumburg, IL
33. Burlington Mall, Burlington, MA
34. Arundel Mills, Hanover, MD (location #1)
35. Arundel Mills, Hanover, MD (location #2)
36. Concord Mills, Concord, NC
37. Haywood Mall, Greenville, SC
38. The Mills at Jersey Gardens, Elizabeth, NJ (location #1)
39. The Mills at Jersey Gardens, Elizabeth NJ (location #2)
40. Auburn Mall, Auburn, MA
41. Natick Mall, Natick, MA
42. Philadelphia Mills, Philadelphia, PA
43. Glendale Galleria, Glendale, CA
44. Pioneer Place, Portland, OR
45. The Shops at Mission Viejo, Mission Viejo, CA
46. Northshore Mall, Peabody, MA
47. Towson Town Center, Towson, MD
48. Livingston Mall, Livingston, NJ
49. Woodland Hills Mall, Tulsa, OK
50. Fox River Mall, Appleton, WI
51. Bay Park Square, Green Bay, WI
52. Oak Park Mall, Overland Park, KS
53. Rockaway Townsquare, Rockaway, NJ
54. Woodland Hills Mall, Tulsa, OK
55. Montgomery Mall, North Wales, PA
56. Newport Centre, Jersey City, NJ
57. Market Place Shopping Center, Champaign, IL
58. Southridge Mall, Greendale, WI
59. Lehigh Valley Mall, Whitehall, PA
60. McCain Mall, North Little Rock, AR
61. Solomon Pond Mall, Marlborough, MA
62. Woodbury Common Premium Outlets, Central Valley, NY
63. The Maine Mall, South Portland, ME
64. Quaker Bridge Mall, Lawrenceville, NJ
65. The Mall at Rockingham Park, Salem, NH
66. Harford Mall, Bel Air, MD
67. Connecticut Post Mall, Milford, CT
68. Southlake Mall, Merrillville, IN
69. The Mall of New Hampshire, Manchester, NH
70. The Shoppes at Buckland Hills, Manchester, CT
71. Park Plaza, Little Rock, AR
72. Greenwood Mall, Bowling Green, KY
73. The Mall in Columbia, Columbia, MD
74. Burnsville Center, Burnsville, MN
75. Meadowood Mall, Reno, NV
76. Park City Center, Lancaster, PA
77. Coastal Grand Mall, Myrtle Beach, SC
78. Columbiana Centre, Columbia, SC
79. CoolSprings Galleria, Franklin, TN
80. Square One Mall, Saugus, MA
81. Fashion Valley, San Diego, CA
82. Louis Joliet Mall, Joliet, IL
83. St Charles Towne Center, Waldorf, MD
84. Mid Rivers Mall, St Peters, MO
85. Northpark Mall, Joplin, MO
86. Pheasant Lane Mall, Nashua, NH
87. Monroeville Mall, Monroeville, PA
88. Houston Galleria, Houston, TX
89. Towne East Square, Wichita, KS
90. Mall St Matthews, Louisville, KY
91. Riverchase Galleria, Hoover, AL
92. Christiana Mall, Newark, DE
93. Fox Valley Mall, Aurora, IL
94. Four Seasons Town Centre, Greensboro, NC
95. West Town Mall, Knoxville, TN
96. Town Center at Aurora, Aurora, CO
97. Westfarms, W Hartford, CT
98. Crossroads Center, St Cloud, MN
99. Northlake Mall, Charlotte, NC
100. SouthPark, Charlotte, NC
101. Monmouth Mall, Eatontown, NJ
102. Cherry Hill, Cherry Hill, NJ
103. Ocean County Mall, Toms River, NJ
104. Roosevelt Field, Garden City, NY
105. La Plaza Mall, McAllen, TX

About Green Growth Brands Inc.
Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S., its CBD presence at ShopSeventhSense.com, in malls across the country and at DSW shoe stores—and that’s just the beginning. Learn more about our vision at GreenGrowthBrands.com.

About Seventh Sense Botanical Therapy
Seventh Sense Botanical Therapy offers CBD-infused botanical body care using the finest ingredients on earth. Crafted with wellness in mind, Seventh Sense aims to make CBD an accessible part of self-care routines across the country. Discover the magic of CBD at shops across the country and online at ShopSeventhSense.com.

Cautionary Statements:
Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions.  Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018 which is available on the Company’s issuer profile on SEDAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including, but not limited to, the Company’s ability to execute on its growth strategy, the Company’s vision to become a multi-state operator with retail stores exceeding certain financial thresholds, is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act“), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

$GNPX Significant Step in Manufacturing for Oncoprex

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018.

Genprex’s initial product candidate, Oncoprex™ consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge. Historically, the manufacturing steps of combining the plasmid DNA with the lipid nanovesicles of Oncoprex, has been done for Genprex at MD Anderson Cancer Center. Since Genprex’s IPO, the company has been working to transfer and scale up these processes through other contract manufacturers.

“Each successful release of plasmid DNA batches is an important milestone for Genprex as it allows us to not only demonstrate continued progress in coordinating scale-up manufacturing of Oncoprex, but it takes us one step closer to re-entering the clinic with both our EGFR program and our immunotherapy combination programs. Biologics manufacturing, especially for lipid nanoparticle (or LNP) delivered gene therapy, is a complex process, but one we tackle with pride alongside dedicated partners such as Aldevron, through a similar vision to deliver innovative therapies to patients with significant unmet medical needs,” said Julien Pham, MD, Genprex’s President and Chief Operating Officer.

The U.S. Food and Drug Administration (FDA) has made manufacturing a top priority for cell and gene therapy companies. The FDA’s former Commissioner, Scott Gottlieb, noted in 2018 that the agency devotes approximately 80 percent of its focus during reviews of gene therapy candidates to manufacturing and quality concerns. FDA’s Director of the Center for Drug Evaluation and Research, Janet Woodcock, M.D., noted in July 2019 that the agency is adapting to the flood of new drug applications stemming from advances in gene therapy and is shifting its stance toward drug development more than in recent years. This shift emphasizes the need for gene therapy companies to not only demonstrate clinical efficacy but also be able to manufacture these drugs on a large scale.

Genprex has made manufacturing one of its top priorities since its IPO in 2018. During that time, Genprex has been building out its manufacturing process development to support this expansion and advance its commercial scaling capabilities.

Earlier this year, Genprex strengthened its senior team with the appointment of Eric Chapdelaine as Senior Director of Pharmaceutical Sciences and Manufacturing to support the company’s manufacturing, technical operations, and supply chain management.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of TUSC2 on cancer, the effect of products and services provided by Aldevron and our other commercial partners on the development of Oncoprex™, the build-out, transfer and scale-up of our manufacturing processes, our current and planned clinical trials, and the commercialization of our product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of TUSC2’s effect on cancer, our ability to utilize the products and services of Aldevron and our other commercial partners, the ability of those products and services to influence the development of Oncoprex™, our ability to successfully build-out and scale-up our manufacturing process, our ability to successfully transfer manufacturing processes to commercial maufacturers, as well as the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex™ and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

$CNPOF $RIV.V Acquisition of Vertically-Integrated Pennsylvania Cannabis Operator

TORONTO, Aug. 6, 2019  – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSXV: RIV) (OTC: CNPOF ) is pleased to announce its portfolio company, TerrAscend Corp. (“TerrAscend“) (CSE: TER) (OTCQX: TRSSF), has signed a definitive agreement to acquire Ilera Healthcare (“Ilera“), a vertically-integrated cannabis cultivator, processor, and dispensary operator in Pennsylvania. Ilera’s state-of-the-art, fully integrated seed-to-sale operations adds to TerrAscend’s growing global footprint, currently spanning multiple U.S. states, Canada and the European Union.

“TerrAscend’s rapid expansion in the U.S. has been driven by strategic, accretive acquisitions of quality operators with strong track records of success,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “We view the Ilera acquisition as another important step by TerrAscend as it grows its revenue-generating operations, expands its U.S. footprint in new states, and continues to scale its global business operations.”

Ilera is one of only five operators in the state of Pennsylvania to have been awarded a “super licence” to grow, process and sell cannabis. Through its state-of-the-art facility in Waterfall, Pennsylvania, Ilera has a genetic library of more than 170 cannabis strains, a modern greenhouse designed for optimal plant growth and minimal environmental impact, clean CO₂ and ethanol extraction capabilities, and cutting-edge packaging technology. In addition to selling its products in its own dispensary, Ilera distributes its dried flower, concentrates, tinctures, and topicals to 50 of Pennsylvania’s 52 medical cannabis dispensaries. With this acquisition, TerrAscend plans on launching its own suite of brands in the Pennsylvania market, including its California-based Valhalla Confections and State Flower brands as well as its premium Canadian cannabis brand, Haven St.

For more information, including the terms of the transaction, see TerrAscend’s announcement here.

In October 2018, to accommodate TerrAscend’s strategic pursuits internationally, including select opportunities in the United States, Canopy Rivers agreed to restructure its investment and waive certain restrictive covenants that were granted by TerrAscend, in connection with its original investment. For more information regarding Canopy Rivers’ investment in TerrAscend, please refer to the Company’s annual information form dated July 15, 2019 (“AIF“), filed with Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com. For additional information about TerrAscend, please refer to TerrAscend’s profile on SEDAR or their website at www.terrascend.com.

About Canopy Rivers:

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: TerrAscend’s global footprint and the impact of the Ilera acquisition thereon; the potential impact of the Ilera acquisition on TerrAscend’s business and future growth; TerrAscend’s plans to launch its own suite of brands in the Pennsylvania market, including its Valhalla Confections, State Flower and Haven St. brands; and other expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; the actual impact of the Ilera acquisition on TerrAscend’s business, global footprint and future growth; TerrAscend’s ability to launch its own suite of brands in Pennsylvania; changes in consumer demand and preferences; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ AIF, filed with Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

$YGYI Texas State Police Memo Instructs Officers to Stop Cannabis Possession Arrests

$PBIO Solves CBD Water-Solubility Problem with Patented UST Platform

$LXRP Paves Way for New Cannabis Brand

• Lexaria Bioscience’s revolutionary DehydraTECH technology enables cannabis consumers to experience rapid-on, rapid-off effects in non-smoked formulations
• A just-announced joint manufacturing partnership between Lexaria and alcohol-free beverage maker Hill Street Beverage Company is paving the way for wider distribution of Lexaria’s platform
• Hill Street is the only company to have gained licenses to use DehydraTECH on a global basis, taking advantage of Lexaria’s multiple international granted and pending patents
• By 2024, cannabis-infused beverage sales are expected to rise by nearly 15 times from last year’s revenues of $89 million

The exploding interest in cannabis products and in new ways of enjoying them has proven fertile ground for drug technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) as it markets the company’s revolutionary DehydraTECH platform for increasing the absorption rates of varied edible substances, including nicotine and cannabidiol (CBD).

DehydraTECH is a drug delivery technology that gets ingested active pharmaceutical ingredient (API) molecules to the bloodstream faster than other methods. Under a new agreement announced…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$BHAT Knows that the Toy Business is Not a Game

• Blue Hat reported 52 percent revenue growth and 76 percent net income growth for the nine months ended September 30, 2018
• The company maintains a vast portfolio of proprietary technologies, patents, artwork copyrights, trademarks and software copyrights
• Retail sales of toys and games in China surged from RMB111.8 billion in 2012 to RMB276.6 billion in 2017
• Global trends and government policies favor further growth

The toy industry is not a frivolous pastime. In fact, the toy business offers a wealth of opportunity. The United States is currently the largest segment of global toy sales. However, in terms of growth prospects, the toy market in Asia is on a tear, growing by a whopping 20 percent from 2012 to 2017. China’s market for toys and video games, now worth $45 billion, is expected to bypass America in just a few years (http://nnw.fm/2pUDX). With this expansion, modern consumers are looking for unique products that go far beyond the typical and deliver a wow factor.

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) delivers that wow factor, creating the toys and games that…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://nnw.fm/BHAT

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$INMB Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer

LA JOLLA, Calif., Aug. 05, 2019 — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported positive preliminary data today during a presentation at Cambridge Healthtech Institute’s 7^th Annual Immuno-Oncology Summit in Boston. INB03 is being developed as part of combination immunotherapy to potentially reverse resistance to treatment.

The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by a dominant-negative technology. Today, positive preliminary data from the first two cohorts were released. These data will be followed by a final report later this year as the company advances the program into a Phase II study.

“The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,” said RJ Tesi, MD, Chief Executive Officer and Chief Medical Officer of INmune Bio. “All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.”

To date, 11 of 12 patients have been enrolled in one of three dosing cohorts of INB03 (0.3, 1.0 and 3.0 mg/kg). Participants were a mix of patients with advanced solid tumors that have progressed after multiple previous lines of therapy. INB03 was given once a week by subcutaneous injection. Safety, INB03 pharmacokinetics and inflammatory biomarkers were followed in all patients.

Preliminary data from patients treated in the first two cohorts are available. Patients included two males and four females, and the average age was 63-years-old. Patients in the study had prostate cancer, ovarian cancer, colon cancer (two), cholangiocarcinoma and lung cancer, with an average of three previous lines of therapy (range: two to four). INB03 was given for a median of 74 days (range: 12 to 119 days). No drug-related serious adverse events have been reported, and INB03 was well tolerated. Discontinuation of INB03 was due to tumor progression in all patients. INB03 trough drug levels were obtained before each INB03 dose. The target INB03 trough level was reached in three of three patients in the 1.0 mg/kg group. The inflammatory cytokine IL6, a biomarker of soluble TNF function, decreased by more than 50% in half of the patients, suggesting a pharmacodynamic effect of INB03.

About INB03
INB03, a novel dominant-negative TNF inhibitor, is a selective second-generation TNF inhibitor that neutralizes soluble TNF (sTNF) without blocking the function of trans-membrane TNF or TNF receptors. In animal studies, INB03 neutralization of sTNF alters the immunobiology of the tumor microenvironment (TME) to improve tumor killing by decreasing populations of cells in the TME that protect the tumor from the patient’s immune system and immunotherapy – myeloid derived suppressor cells, T regulatory cells and tumor activated macrophages. The unique mechanism of action suggests INB03 may have safety and efficacy advantages over currently approved non-selective TNF inhibitors in the treatment of cancer and other diseases.

About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms that reengineer the patient’s innate immune system’s response to disease. In addition to INB03, INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. XPro1595 targets neuroinflammation, which causes microglial activation, neuronal cell death and synaptic dysfunction. XPro1595 is enrolling patients in a Phase I trial in Alzheimer’s disease that is supported by a $1M Part-the-Cloud Award from the Alzheimer’s Association. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and neurodegenerative diseases. To learn more, please visit www.inmunebio.com.

Safe Harbor Statement
                                                                                                                             
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.  INBO3 is still in clinical trials and has not been approved and there cannot be any assurance that it will be approved.  The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange  Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Media Contact:
Antenna Group
Holly Dugan
(201) 465-8019
INmuneBio@AntennaGroup.com

Investor Contact: 
KCSA Strategic Communications
Valter Pinto / Scott Eckstein
PH: (212) 896-1254 / (212) 896-1210
INmune@KCSA.com

$BHAT Creating Augmented Reality Toys, Games for Youth in China

• Retail sales of toys and games in China soared from RMB111.8 billion in 2012 to RMB276.6 billion in 2017, registering an average annual growth rate of nearly 20 percent
• Favorable Chinese government policies emphasize the research and development of new technologies such as augmented reality (AR) and virtual reality (VR)
• The global trend toward AR and VR products is expected to increase dramatically from 2018 to 2025, with market value projected to reach $767 billion
• Blue Hat owns an extensive portfolio of proprietary technologies, patents, artwork copyrights, trademarks and software copyrights

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) is a leading producer, developer and operator of augmented reality (AR) games and smart toys in China for children and young adults ages three to 23. The company’s product line includes interactive educational materials, mobile games and toys with mobile game features. Blue Hat’s mobile-connected entertainment platform enables the connection of physical items to mobile devices through wireless technologies, creating a unique interactive user experience.

The global augmented reality (AR) and virtual reality (VR) market is expected to thrive over the foreseeable future, according to Market Research Future analysis published February 12, 2019. The report suggests that the AR/VR market value is…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://nnw.fm/BHAT

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$INMB Presents Cancer Treatment Immunotherapy at #IDDST 2019

• INmune Bio attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan
• Co-founder and CEO R.J. Tesi and Director of Neuroscience C.J. Barnum both participated in talks about the role of immunotherapy in the treatment of specific medical conditions
• The congress was a paramount event in the field of immunotherapy, allowing researchers to network, exchange ideas and discuss recent developments

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease, presented its innovative cancer immunotherapy, as well as its Alzheimer’s disease drug candidate, during a major immunotherapy industry congress.

The 17th Annual Congress of International Drug Discovery Science & Technology, held on July 26 in Japan, brought together several immunotherapy industry leaders and…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$PBIO Provides Proprietary Benchtop UST Instrument to Ohio State Scientists

$TGODF Successfully Renews Health Canada Licences for Ancaster Site Until 2022

The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF) is pleased to announce that it has successfully renewed its Health Canada licences for the Company’s Ancaster, Ontario facility until August 2022.  As per the Cannabis Regulations, these licences authorize TGOD to cultivate, process and sell cannabis from its Ancaster site.

“From day one, the entire team at TGOD placed a strong focus on ethics and compliance. These core values have been paramount to our success,” commented Brian Athaide, CEO of TGOD. “Our team continues to work diligently as we ramp up production and execute our business plan.”

TGOD is in the process of completing its third building at Ancaster, a state-of-the-art hybrid greenhouse. Completion is expected by the end of the month, bringing the facility to a total size of 166,000 square feet with an annual production capacity of 17,500 kgs; TGOD is also seeking an eGMP certification to allow for global exports, as laws and regulations permit.

About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about future facility construction, statements about future production capacity, statements about the achievement of certain certifications in connection with its facilities, statements about the receipt of any regulatory permits or licences, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

$GGBXF Announces Acquisition Closing of Florida-Based Spring Oaks

COLUMBUS, OH, Aug. 1, 2019 – Green Growth Brands, Inc. (CSE: GGB) (OTCQB: GGBXF) (“GGB” or “the Company”) is pleased to announce the completion of its previously announced acquisition of Spring Oaks Greenhouses, Inc. (“Spring Oaks”),  per the terms detailed on July 29, 2019.

The closing of this acquisition brings GGB’s ability to operate dispensaries up to 47 across three key states: Nevada, Massachusetts and Florida.

About Green Growth Brands Inc.
Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S., its CBD presence at ShopSeventhSense.com, in malls across the country and at DSW shoe stores—and that’s just the beginning. Learn more about our vision at GreenGrowthBrands.com.

Cautionary Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions.   Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018 which is available on the Company’s issuer profile on SEDAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including, but not limited to, the Company’s ability to execute on its growth strategy, the Company’s vision to become a multi-state operator with retail stores exceeding certain financial thresholds, is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

$CNPOF $RIV Health Canada Approval for Radicle’s Production Facility Expansion

$TGODF 420 with CNW – Federal Court Orders DEA to Explain Cannabis Research Block

$BHAT Finalizes Strategic Agreement to Equip Schools with Smart AR Tech

• A strategic partnership is expected to enable Blue Hat to modernize classrooms across Guangzhou, China
• Through the agreement, Blue Hat will begin the development of augmented reality solutions for the education sector
• VR and AR are prominent in China, where both the government and provincial authorities are encouraging the introduction of technological initiatives in the field of education

Chinese augmented reality software developer Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) announced on April 30 the finalization of a strategic agreement with Guangdong Family Periodicals Group.

Through the partnership, the two enterprises will work toward the development of innovative educational solutions that feature Blue Hat’s innovative technologies, as the company detailed in…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://nnw.fm/BHAT

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com